Actelion wins another approval for Opsumit

|About: Actelion Ltd. (ALIOF)|By:, SA News Editor

The European Commission has approved Actelion's (ALIOF +1.6%) Opsumit for PAH as a monotherapy or in conjunction with other PAH treatments. (PR)

The FDA approved the drug in October.

As FierceBiotech notes, the approvals should give the company a bit of a cushion as Tracleer goes off patent in 2015.